Yasuo Urata, has more than 30 years of experience in the pharmaceutical industry.  He established Oncolys BioPharma Inc. in 2004 in Tokyo, Japan where his mission to contribute to the advancement of medical science in the world through bringing innovation to the existing treatments for cancer and serious infections diseases, using virology-based new drug discovery technologies came to life.
Mr. Urata served various executive functions at Japan Tobacco pharmaceutical division (JT Pharmaceutical), including Director of R&D Planning. During the time of JT from 1994 to 2004, he launched the innovative HIV drug, Viracept® with Agouron and led many drug development projects such as GVAX project with Cell Genesys and the cancer vaccine project with Corixa. He also, served as clinical project leader mainly for cardiovascular and central nerve system fields at Ono Pharmaceutical Co. He became a member of the Bio Innovation Research Society in 2009.

Mr. Urata became the Executive Officer of Oncolys USA Inc. in 2016. Mr. Urata received his B.Sc. and M.Sc. from Kyoto Pharmaceutical University.

Talia Biran joined Oncolys USA Inc. in 2017, with over 25 years of experience in Medical affairs. Having worked at Janssen, Merck and Novartis, she contributed to the development and launch of Abiraterone Acetate (Zytiga ®, prostate cancer), Vorinostat (Zolinza®, CTCL), Letrozole (Femara®, breast cancer) and Octreotide (Sandostatin LAR®, neuroendocrine tumors (NETs) and acromegaly)
Prior to Oncolys, Talia played a pivotal role at Lexicon Pharmaceuticals as Executive Director, where she established the US medical affairs infrastructure for Oncology and Diabetes programs and led the development and launch of Lexicon's first drug candidate, Telotristat Ethyl ( Xermelo, ® Carcinoid Syndrome Diarrhea) (Licensed Ex-US to Ipsen Inc)

Talia holds a Master of Science (M.Sc) in Microbiology from Tel-Aviv University, Department of Life Sciences, in Tel-Aviv, Israel. Her thesis, under the supervision of Professor Sara Lavi, focused on Gene Amplification of SV-40 and its link to tumorigenesis.

Qualified in medicine at Karolinska Institute, Stockholm, Sweden with 30+ years in big pharma and biotech R&D functions including clinical research, pharmacovigilance, medical affairs, strategic product development and general management. Held roles at local, European and global level while at Glaxo Smith Kline, Pharmacia, Wyeth and Bristol Myers Squibb. Most recently CMO at Targovax leading the development of the oncolytic virus ONCOS-102 from preclinical to registrational path. Therapeutic area expertise in immune oncology.

Extensive investor relations interactions and network in Europe and USA. Analyst go to person while at Targovax, instrumental in securing listing on the Oslo stock exchange and raising $100 million during 2015 - 2021.

Honorary Lecturer in drug development at King’s College, London 2005 – 2010. Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and the Royal Society of Medicine.